Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Advanced BRCA-Mutated Ovarian Cancer
NCT00494442Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2007
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label trial of olaparib in ovarian cancer, sponsored by AstraZeneca. Primary endpoint: Confirmed Objective Tumour Response. Started Jun 2007; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00494442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00494442.